Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.70 |
| ▸ | MAOA | P21397 | 11/20 | 0.70 |
| ▸ | F12 | P00748 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11462954 | 0.84 | MAOB (0.91) | MAOBMAOAF12MAPK1NPC1 | |
| SCHEMBL831792 | 0.83 | MAOB (1.00) | MAOBMAOAF12MAPK1NPC1 | |
| SCHEMBL28656523 | 0.82 | MAOB (1.00) | MAOBMAOAF12MAPK1NPC1 | |
| SCHEMBL13593311 | 0.80 | PLG (0.67) | MAPK1NPC1 | |
| SCHEMBL4389144 | 0.80 | MAOA (1.00) | MAOBMAOAF12MAPK1NPC1 | |
| SCHEMBL4972712 | 0.80 | MAOB (1.00) | MAOBMAOAF12MAPK1CA12 | |
| SCHEMBL6228344 | 0.78 | MAOB (1.00) | MAOBMAOAF12MAPK1NPC1 | |
| SCHEMBL5655976 | 0.77 | NPC1 (0.68) | MAOBMAOAF12MAPK1AKR1B10 | |
| SCHEMBL31661779 | 0.77 | NPC1 (0.68) | MAOBMAOAF12MAPK1AKR1B10 | |
| SCHEMBL14476486 | 0.76 | MAPK1 (1.00) | MAOBMAOAF12MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | MAOB 2398/4885MAOA 2551/4885F12 326/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | MAOB 3075/4885MAOA 4186/4885F12 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.